<DOC>
	<DOCNO>NCT02762617</DOCNO>
	<brief_summary>This prospective , two-site , two-arm , randomize , single-blind , placebo-controlled trial examine safety pharmacokinetics ( PK ) polyurethane tenofovir disoproxil fumarate ( TDF ) vaginal ring use continuously 84 consecutive day sexually active woman . The primary objective ass safety TDF vaginal ring use continuously 84 day healthy , HIV-uninfected , sexually active woman , compare placebo vaginal ring .</brief_summary>
	<brief_title>Safety Pharmacokinetics ( PK ) Polyurethane Tenofovir Disoproxil Fumarate ( TDF ) Vaginal Ring ( TDF IVR-002 )</brief_title>
	<detailed_description />
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Age 1845 year ( inclusive ) screening . General good health ( volunteer history per investigator discretion ) without clinically significant systemic disease ( include , limited significant liver disease/hepatitis , gastrointestinal disease , kidney disease , thyroid disease , osteoporosis bone disease , diabetes ) . Able willing provide write informed consent screen take part study . Able willing provide adequate locator information . Able willing avoid receptive vaginal anal intercourse 1 week biopsy . HIVuninfected base test perform study staff screening procedure ( per applicable algorithm Appendix II ) . Using copper IUD hormonal contraceptive method , IVR , minimum 2 month intend use method duration study participation . Per participant report , sexually active , define vaginal intercourse least month prior screen . Have regular sex partner willing least 4 sex act per month duration study . Sex act define penilevaginal penetrative intercourse . Study staff provide condom study participant . Participants restrict engage oral sex . Has use pre postexposure prophylaxis HIV exposure 3 month prior Screening . Per participant report Screening Enrollment , agree participate research study involve drug , medical device , vaginal product duration study participation . At Screening , participant state able willing refrain take traditional herb medicine willing refrain insert nonstudy vaginal product object vagina , include limited , spermicide , diaphragm , contraceptive vaginal ring , vaginal medication , vaginal probiotics/prebiotics , menstrual cup , cervical cap ( vaginal barrier method ) , douche , lubricant , vaginal drying agent sex toy ( vibrator , dildo , etc. ) . Tampons may use , menses . Vaginal cervical anatomy , opinion investigator , lend easy genital tract sample collection . Women must meet none follow criterion prior genital sample Enrollment : Participant report follow Screening : Sex past 3 month possibility sex study participation partner HIV+ partner unknown HIV status . Known adverse reaction polyurethane component study product allergy silver nitrate Monsel 's solution . Active hepatitis B infection . Chronic , recurrent , and/or acute vulvar vaginal symptom ( pain , irritation , spot , etc. ) . Known bleed disorder could lead prolonged continuous bleed biopsy . Intending become pregnant period study participation . Currently breastfeed plan breastfeed course study . Menopause . History unexplained unresolved intermenstrual bleed 3 month prior screen . History gynecological procedure ( include genital piercing ) external genitalia , vagina cervix last 14 day . Hysterectomy . Women use contraceptive IVRs study product IVR . Systemic use last 2 week anticipate use study period follow : corticosteroid , anticoagulant ARVs . Plans relocate away study site area period study participation . Grade 1 high laboratory abnormality , define DAIDS Table Grading Severity Adult Pediatric AEs , Version 2.0 , Nov 2014 . At Screening Enrollment , pregnant ( base urine pregnancy test ) . In last three month , diagnose treated STI . Note : Women history condylomata genital herpes may consider eligibility long lesion exam . HSV 1 2 serology obtain . Participants include regardless result serology . Reproductive tract infection ( RTI ) pelvic inflammatory disease ( PID ) require treatment per local guideline Kenya CDC guideline US Screening Enrollment . Note : Otherwise eligible woman diagnose symptomatic vulvovaginal candidiasis ( VVC ) , symptomatic BV urinary tract infection ( UTI ) eligible Visit 2 ( Enrollment ) schedule symptom resolve least two week complete treatment . Women recurrent VVC symptomatic BV despite treatment offer another course treatment eligible . Positive test Trichomonas vaginalis , Neisseria gonorrhea Chlamydia trachomatis screening . Positive test hepatitis B ( define positive hepatitis B surface antigen ) . Reactive serologic test syphilis screening ( per local guideline ) . Note : Women history syphilis acquire and/or treat within past 3 month appropriately treat may consider eligibility . At Screening Enrollment , clinically apparent Grade 1 high pelvic exam finding ( observe study clinician designee ) per DAIDS Table Grading Severity Adult Pediatric AEs , Addendum 1 , Female Genital Grading Table Use Microbicide Studies . Note : Cervical friability bleeding associate speculum insertion and/or specimen collection judge within range normal accord clinical judgment PL/designee consider expect nonmenstrual bleeding exclusionary . Pap result Grade 2 high accord Female Genital Grading Table Use Microbicide Studies Addendum 1 DAIDS Table Grading Adult Pediatric AEs , Version 1.0 , December 2004 ( Clarification date August 2009 ) . Note : Women 21 year age older document normal result within 12 month prior enrollment need Pap smear screening period . Women Grade 1 abnormal Pap smear enrol upon completion initial phase evaluation current treatment indicate ( base local standard care management abnormal cervical cytology ) . Need repeat Pap within 6 month preclude enrollment prior result become available . At Screening , severe pelvic relaxation either vaginal wall uterine cervix descend beyond vaginal introitus Valsalva maneuver . Has condition , investigator 's opinion , would preclude informed consent , make study participation unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Women 's Health</keyword>
</DOC>